On August 7, 2026, Wave Life Sciences completed a redomiciliation from Singapore to Delaware via a statutory scheme of arrangement. All issued ordinary shares of the former Singapore parent were exchanged on a one-for-one basis for newly issued common stock of the new Delaware parent, Wave Life Sciences, Inc. The Singapore entity became a wholly owned subsidiary and its shares will be delisted from Nasdaq prior to August 10, 2026. Trading in the new Delaware common stock under symbol 'WVE' begins on that date. Existing directors and executive officers assumed their roles in the new entity, and equity incentive plans were amended and restated to reference Delaware shares. The company operates in the biotechnology industry, focusing on the discovery and development of small molecule therapeutics.

Wave Life Sciences Ltd. reported financial results for the quarter ended June 30, 2026, recognizing $2.3 million in revenue compared to $8.7 million in the prior year period. The company incurred a net loss of $69.4 million against $50.5 million previously, driven by research and development expenses of $51.3 million and general and administrative costs of $24.8 million. Cash, cash equivalents, and marketable securities totaled $490.6 million as of June 30, 2026, providing an expected cash runway into the third quarter of 2028. Clinically, dosing has commenced in the Phase 2a multidose portion of the INLIGHT trial for WVE-007 in obesity, with combination and maintenance trials scheduled to initiate in the second half of 2026. Additionally, an FDA meeting regarding a potential accelerated approval pathway for WVE-006 in alpha-1 antitrypsin deficiency is set for late summer 2026, while a clinical trial application for WVE-008 remains on track for the second half of 2026. Wave Life Sciences Ltd. operates as a clinical-stage biotechnology company focused on developing RNA medicines to treat rare and common disorders.

On June 22, 2026, shareholders of Wave Life Sciences Ltd. approved a Scheme of Arrangement to facilitate the company's redomiciliation. The proposal passed with 155,190,836 shares voting in favor and 78,429 shares voting against. The company will now seek final approval from the High Court of the Republic of Singapore, with the redomiciliation expected to take effect in mid-2026. Wave Life Sciences is a biotechnology company that develops RNA-based therapeutics.